Eight Roads Launches US$400M Healthcare Fund for China

Eight Roads, a Shangai, China-based global investment firm backed by Fidelity, launched its US$400m latest healthcare fund for China.

Eight Roads China Healthcare Fund V will follow Eight Roads’ core strategy of healthcare investments in China, which is to develop a comprehensive healthcare ecosystem across the industry value chain and around critical diseases.

Led by Daniel Auerbach, Senior Managing Partner and Head of Global Ventures, and Jarlon Tsang, Managing Partner and Head of China at Eight Roads, the new fund will invest in and build innovative and transformational healthcare and life science companies with disruptive technologies and innovative business models that address the unmet market demand. It will primarily focus on early-stage investment opportunities in the healthcare industry, covering therapeutics, med tech, healthcare services and healthcare IT/digital health.

Today, Eight Roads has backed over 50 healthcare companies in China spanning drug discovery and development (WuXi Apptec, Innovent Biologics, Hua Medicine, Adagene, Insilico Medicine, Westlake Therapeutics, Semma Therapeutics, OcuMension), domestic leading med tech (EyeBright, Nanos Medical, b-ONE, LenoMed, RedPine), traditional and innovative healthcare services (DeltaHealth, BangEr Orthopaedic Hospital, Gushengtang, Arion, TreeENT, OST, KnowYourself), and digital solutions that improve the efficiency of medical payment and health care (Medbanks, MediTrust, FuCunBao, Haici Technology, Wanhu Health).

Globally, Eight Roads has an extensive network of investors and operators in offices across China, Japan, India, Europe and the US. To date, it has invested in more than 200 companies globally in healthcare, of which 34 have completed an initial public offering (IPO) on a stock exchange in mainland China, Hong Kong or the US, including WuXi Apptec, Adagene, Beam Therapeutics, Denali Therapeutics, EyeBright, Hua Medicine, Innovent Biologics, Laurus Labs, NKF, OcuMension, etc.